Work Here?
United States Drug Testing
Work Here?
Specialized toxicology drug screening services
United States Drug Testing
Work Here?
Specialized toxicology drug screening services
Overview
USDTL provides toxicology testing services using advanced drug screening in hair, nail, and umbilical cord tissue for healthcare providers, legal entities, and research institutions. Clients submit samples and USDTL runs panel-based analyses, delivering results with interpretations. They differentiate themselves by using matrices beyond blood or urine and by offering customized testing panels. Their goal is to be a leading provider of fast, precise, and reliable drug-screening across multiple specimen types.
About United States Drug Testing
Industries
Data & Analytics
Government & Public Sector
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Des Plaines, Illinois
Founded
1991
Get referred to United States Drug Testing
See people who can refer or advise you
Simplify's Take
What believers are saying
- January 2025 Northlane backing funds acquisitions, automation, and sales expansion.
- 2025-2026 panels added ketamine, xylazine, gabapentin, and tianeptine detection.
- CourtFact integration should lift referrals from courts, probation, and treatment networks.
What critics are saying
- Northlane ownership can force growth targets before laboratory operations fully scale.
- USDTL's January 2026 clinical expansion invites MedTox, Labcorp, and Quest retaliation.
- SAMHSA certification changes or quality failures would cripple federal testing revenue quickly.
What makes United States Drug Testing unique
- USDTL owns niche hair, nail, and umbilical-cord toxicology workflows.
- January 2026 CourtFact integration embeds USDTL inside justice-program case management.
- January 2026 clinical-specimen launch broadens USDTL beyond forensic-only testing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Paid Vacation
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Brown Gibbons Lang & Company (BGL) announced the sale of United States Drug Testing Laboratories (USDTL) to Northlane Capital Partners (NCP). BGL acted as the exclusive financial advisor for the transaction, with terms undisclosed. USDTL, based in Des Plaines, Illinois, provides alcohol and substance testing services. The partnership with NCP aims to enhance USDTL's testing capabilities and expand its customer base.
Northlane Capital Partners (NCP) has invested in United States Drug Testing Laboratories Inc. (USDTL), a forensic toxicology lab. NCP joins USDTL's founders, Veronica and Doug Lewis, as the first institutional partner. Albert Berger is appointed CEO to lead expansion. NCP aims to leverage its expertise to support USDTL's growth. NCP, based in Bethesda, MD, has invested over $1.7 billion in healthcare and business services sectors.
USDTL has also appointed Albert Berger as Chief Executive Officer to lead the next phase of the company's expansion.
United States Drug Testing is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About United States Drug Testing
Industries
Data & Analytics
Government & Public Sector
Healthcare
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Des Plaines, Illinois
Founded
1991
United States Drug Testing is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today